ATM

Lilly's Weight Loss Drug Gains Traction After Novo Nordisk's Clinical Trial Setback

3 days ago

In a significant turn of events, shares of Eli Lilly surged following news that competitor Novo Nordisk faced challenges in its clinical trials for a key weight loss drug. This development highlights a growing advantage for Lilly in the realm of obesity treatments, potentially reshaping the competitive landscape of the pharmaceutical industry.

End of Shortage: FDA Declares Lilly's Weight Loss Drug Readily Available in the U.S.

4 days ago

In a significant development for the U.S. healthcare landscape, the Food and Drug Administration (FDA) has announced that the shortage of Eli Lilly's groundbreaking weight loss medication, semaglutide, has officially come to an end. This news comes as a relief to countless individuals grappling with obesity and seeking effective treatments to support their weight loss journeys.

Novo Nordisk Dedicates $1.2 Billion to New State-of-the-Art Factory in Denmark

7 days ago

In a significant move for the pharmaceutical industry, Novo Nordisk has announced an impressive investment of $1.2 billion to build a new factory in Denmark. This major initiative is aimed at enhancing the company's production capabilities, particularly for its expanding portfolio in diabetes and obesity treatments. With the global demand for such products skyrocketing, this new facility is positioned to bolster Novo Nordisk's role as a leader in the biotechnology sector.

Surge in At-the-Market Stock Sales: MicroStrategy and Tilray Lead the Charge

8 days ago

In a significant turn of events within the financial markets, several companies have seized the opportunity to engage in robust at-the-market (ATM) stock sales. Notably, MicroStrategy Inc. and Tilray Brands, Inc. are at the forefront of this surge, leveraging the favorable market conditions to bolster their capital reserves.

Nigeria's ATM Crisis: The Rise of Cash Agents Amid Dying Machines

9 days ago

Nigeria finds itself in a peculiar predicament as its Automated Teller Machines (ATMs) face a systemic failure, leading to a significant cash shortage for citizens. The country's ATMs, once seen as a beacon of modern banking, are now struggling to meet the demands of the populace. With many machines malfunctioning or running out of cash, the reliance on cash agents has surged, filling the void left by the unreliable ATMs.

Eli Lilly's Mounjaro Misses Out on Dedicated Sleep Apnea Approval in Europe

10 days ago

In a significant development for the pharmaceutical industry, Eli Lilly's diabetes drug, Mounjaro, has been denied a separate label for the treatment of sleep apnea in Europe. This decision, announced recently, highlights the ongoing complexities within the regulatory landscape governing medical treatments and their approvals across different markets.

Eli Lilly Launches Affordable Zepbound Weight Loss Treatment in Major Move

12 days ago

In a groundbreaking decision aimed at expanding access to weight loss medications, pharmaceutical giant Eli Lilly has announced the rollout of its lower-cost version of the prescription drug Zepbound. This strategic move, set to occur in early 2024, underscores the company's commitment to addressing the growing demand for effective weight management solutions amidst soaring obesity rates in the United States and beyond.

Sandoz Strategizes Quick Launch of Generic Ozempic in Canada

12 days ago

Sandoz, a subsidiary of Novartis, has unveiled its plans to swiftly introduce a generic version of the diabetes medication Ozempic in Canada. This move comes amid rising demand for affordable diabetes treatment options in the country, where the cost of medications has been a significant concern for many patients and healthcare providers alike.

Lilly Plans Trials for Obesity Drugs to Combat Addiction by 2025

13 days ago

In a groundbreaking announcement, Eli Lilly's CEO revealed that the pharmaceutical giant is set to initiate trials in 2025 to explore the potential use of its obesity drugs in treating addiction. This promising development stands as a pivotal moment in both obesity and addiction treatment landscapes.

GSK's Oncology Breakthrough: Transforming Cancer Survival Rates with Innovative Therapy

14 days ago

In a groundbreaking development for cancer treatment, GlaxoSmithKline (GSK) is on the brink of reviving a cancer drug that has shown remarkable potential in improving survival rates for patients battling certain aggressive forms of the disease. This promising news comes from recent clinical trials that have illuminated the drug's efficacy, offering a new ray of hope for those affected by hard-to-treat cancers.